

**On-line Table: Description of the entire cohort and individual study groups**

| Variables                                       | All Patients (n = 54) | MT-I (n = 8)     | MT-END (n = 6)   | IV (n = 40)      |
|---|-----------------------|------------------|------------------|------------------|
| <b>Demographics and risk factors</b>            |                       |                  |                  |                  |
| Female sex                                      | 24 (44.4%)            | 5 (62.5%)        | 2 (33.3%)        | 17 (42.5%)       |
| Age (yr) (median) (min–max)                     | 69 (32–95)            | 63 (32–78)       | 72 (50–81)       | 71 (40–95)       |
| Baseline mRS (median) (min–max)                 | 0 (0–4)               | 0 (0–3)          | 0 (0–4)          | 0 (0–3)          |
| Hypertension                                    | 34 (63.0%)            | 2 (25.0%)        | 4 (66.7%)        | 28 (70.0%)       |
| Diabetes  | 11 (20.4%)            | 2 (25.0%)        | 1 (9.1%)         | 8 (20.0%)        |
| Hyperlipoproteinemia                            | 22 (38.6%)            | 1 (12.5%)        | 3 (33.3%)        | 18 (45.0%)       |
| Smoking   | 10 (18.5%)            | 1 (12.5%)        | 1 (16.7%)        | 8 (20.0%)        |
| Previous stroke                                 | 6 (11.1%)             | 0 (0.0%)         | 0 (0.0%)         | 6 (15.0%)        |
| Atrial fibrillation                             | 18 (31.6%)            | 2 (25.0%)        | 3 (50%)          | 13 (32.5%)       |
| Coronary artery disease                         | 14 (25.9%)            | 1 (12.5%)        | 1 (16.7%)        | 12 (30.0%)       |
| <b>Clinical features</b>                        |                       |                  |                  |                  |
| Baseline systolic blood pressure (mean) (mm Hg) | 161 ± 22              | 150 ± 23         | 165 ± 36         | 163 ± 19         |
| Baseline NIHSS score (median) (min–max)         | 4 (0–5)               | 2 (0–5)          | 4 (2–5)          | 5 (2–5)          |
| NIHSS score before MT (median) (min–max)        | NA                    | 3 (0–5)          | 11.5 (6–18)      | NA               |
| <b>Affected vessel</b>                          |                       |                  |                  |                  |
| ICA/MCA   | 14 (25.9%)            | 2 (25.0%)        | 3 (50%)          | 9 (22.5%)        |
| M1  | 18 (33.3%)            | 6 (75.0%)        | 3 (50%)          | 9 (22.5%)        |
| M2  | 22 (40.7%)            | 0 (0.0%)         | 0 (0.0%)         | 22 (55.0%)       |
| <b>Procedural times and details</b>             |                       |                  |                  |                  |
| OTT (mean) (min)                                | 215 ± 144             | 214 ± 150        | 139 ± 71         | 224 ± 150        |
| DTN (mean) (min)                                | 61 ± 38               | 85 ± 57          | 34 ± 21          | 65 ± 40          |
| DTV (mean) (min)                                | NA                    | 207 ± 144        | 663 ± 534        | NA               |
| rtPA treatment (No.)                            | 54 (94.7%)            | 5 (62.5%)        | 6 (100.0%)       | 40 (100.0%)      |
| Acute carotid stenting (No.)                    | NA                    | 4 (50%)          | 3 (50%)          | NA               |
| Treatment year (median) (min–max)               | 2012 (2002–2015)      | 2015 (2011–2015) | 2013 (2011–2015) | 2011 (2002–2015) |
| <b>Recanalization</b>                           |                       |                  |                  |                  |
| TICI 2b/3                                       | NA                    | 6 (75.0%)        | 6 (100%)         | NA               |
| sICH  | 0 (0.0%)              | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)         |
| <b>Clinical outcome at 90 days</b>              |                       |                  |                  |                  |
| mRS 0–1   | 30 (55.6%)            | 6 (75.0%)        | 2 (33.3%)        | 22 (55.0%)       |
| mRS 0–2   | 38 (70.4%)            | 6 (75.0%)        | 2 (33.3%)        | 30 (75.0%)       |
| mRS 6   | 2 (3.7%)              | 0 (0.0%)         | 1 (16.7%)        | 1 (2.5%)         |

**Note:**—NA indicates not applicable; DTN, door to needle; DTV, door to vessel; min, minimum; max, maximum; OTT, onset to treatment.

<sup>a</sup> Data are number and percentage unless otherwise indicated.